The future of advanced prostate cancer treatment may involve combining ADCs with bispecific T-cell engagers. This strategy could use ADCs for a short duration to deliver a potent hit, followed by immunotherapy to achieve durable remission, potentially reducing toxicity and enabling earlier use.

Despite being considered an 'immune desert' unresponsive to checkpoint inhibitors, germ cell tumors may respond to bi-specific T-cell engagers. These drugs, like one targeting Claudin-6 and CD3, physically bring T-cells to the tumor, potentially bypassing the tumor's inherent immune resistance mechanisms like MHC complex downregulation.

Previously underperforming cancer targets like TIGIT and LAG-3 are seeing renewed interest. Innovative antibody engineering, such as creating bispecific antibodies that target multiple pathways simultaneously, is giving these 'failed' targets new life and potential for clinical success.

A therapeutic approach called "T-cell engagers" or "BiTEs" uses engineered antibodies with two different heads. One side binds to a cancer cell, while the other binds to a nearby T-cell. This effectively brings the killer cell and the target together, leveraging the body's existing immune cells without genetic modification.

An innovative strategy for solid tumors involves using bispecific T-cell engagers to target the tumor stroma—the protective fibrotic tissue surrounding the tumor. This novel approach aims to first eliminate this physical barrier, making the cancer cells themselves more vulnerable to subsequent immune attack.

After standard immunotherapy biomarkers like PD-L1 and TMB proved ineffective in SCLC, the field shifted to a more direct approach. Novel therapies like the bispecific antibody tarlatumab target surface proteins such as DLL3, physically bridging immune cells to cancer cells without relying on predictive biomarkers.

To combat immunosuppressive "cold" tumors, new trispecific antibodies are emerging. Unlike standard T-cell engagers that only provide the primary CD3 activation signal, these drugs also deliver the crucial co-stimulatory signal (e.g., via CD28), ensuring full T-cell activation in microenvironments where this second signal is naturally absent.

While immunotherapy was a massive leap forward, Dr. Saav Solanki states the next innovation frontier is combining it with newer modalities. Antibody-drug conjugates (ADCs) and T-cell engagers are being used to recruit the immune system into the tumor microenvironment, helping patients who don't respond to current immunotherapies.

The bispecific antibody Pumitamig demonstrated identical overall response rates in both PD-L1 positive and negative triple-negative breast cancer patients. This is significant as it provides a potential immunotherapy option for the two-thirds of patients who are PD-L1 negative and currently ineligible for such treatments.